Page last updated: 2024-09-04

ivabradine and Cardiotoxicity

ivabradine has been researched along with Cardiotoxicity in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Aizawa, K; Hayasaka, T; Himuro, M; Ichikawa, T; Ishizawa, K; Ito, S; Nakamura, N; Suzuki, H; Toubai, T; Wanezaki, M; Watanabe, M; Yamada, A; Yamamoto, M; Yanagiya, R1
Abdelaziz, AS; Al-Gareeb, AI; Al-Kuraishy, HM; Batiha, GE; El-Bouseary, MM; Issa, HK; Khalifa, HA; Youssef, A1
Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M1
El-Gowilly, SM; El-Naggar, AE; Sharabi, FM1
Kavtaradze, N; Saganelidze, K1
de Gregorio, C; Ferraro, G; Potenza, G1

Reviews

1 review(s) available for ivabradine and Cardiotoxicity

ArticleYear
[MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Georgian medical news, 2018, Issue:278

    Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Elapid Venoms; Heart; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, C-Type; Neoplasms; Survival Analysis; Trastuzumab; Trimetazidine; Troponin I

2018

Other Studies

5 other study(ies) available for ivabradine and Cardiotoxicity

ArticleYear
Ivabradine as an Adjuvant Agent for Severe Heart Failure Occurring in the Early Phase after Allogeneic Hematopoietic Cell Transplantation.
    Internal medicine (Tokyo, Japan), 2022, Sep-15, Volume: 61, Issue:18

    Topics: Cardiotoxicity; Graft vs Host Disease; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Ivabradine; Transplantation Conditioning; Transplantation, Homologous

2022
The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.
    Inflammopharmacology, 2022, Volume: 30, Issue:6

    Topics: Animals; Cardiotoxicity; Doxorubicin; Ivabradine; Mice; Oxidative Stress; Tumor Necrosis Factor-alpha

2022
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
    The Journal of pharmacology and experimental therapeutics, 2021, Volume: 377, Issue:2

    Topics: Animals; Biomarkers, Pharmacological; Blood Pressure; Cardiotoxicity; Cardiovascular Agents; Heart Rate; Ivabradine; Male; Phenethylamines; Pyridazines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides

2021
Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats.
    Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:1

    Topics: Animals; Arterial Pressure; Autonomic Nervous System; Autonomic Nervous System Diseases; Baroreflex; Cardiotoxicity; Cardiovascular Agents; Cardiovascular System; Disease Models, Animal; Doxorubicin; Heart Failure; Heart Rate; Ivabradine; Male; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure

2018
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity.
    International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Benzazepines; Cardiotoxicity; Dietary Supplements; Drug Therapy, Combination; Female; Humans; Ivabradine; Lisinopril; Middle Aged; Treatment Outcome; Ventricular Dysfunction, Left; Vitamins

2014